02:56 , May 4, 2018 |  BC Innovations  |  Targets & Mechanisms

Solid hopes for T cell bispecifics

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring activated...
01:38 , Sep 17, 2015 |  BC Extra  |  Company News

Amgen, Xencor partner on bispecific antibodies

Amgen Inc. (NASDAQ:AMGN) and Xencor Inc. (NASDAQ:XNCR) partnered to develop six preclinical programs in cancer and inflammation using Xencor's XmAb bispecific antibody platform. Xencor President and CEO Bassil Dahiyat told BioCentury that Xencor will use...
08:00 , Jan 30, 2012 |  BioCentury  |  Strategy

Amgen swallows BiTEs

Amgen Inc. has been interested in acquiring Micromet Inc. for a long time, and finally got the biotech to agree, six months after the companies tested the waters with a discovery and development deal using...
08:00 , Jan 24, 2011 |  BC Week In Review  |  Clinical News

MEDI-565: Phase I started

AstraZeneca's MedImmune LLC subsidiary began a dose-escalation, single-arm, open-label, U.S. Phase I trial to evaluate MEDI-565 in patients with advanced gastrointestinal cancer. Once the maximum tolerated dose (MTD) is established, patients with refractory colorectal...
08:00 , Nov 9, 2009 |  BC Week In Review  |  Company News

Micromet, AstraZeneca deal

Micromet bought out all remaining rights to blinatumomab (MT103) and all other bispecific T cell engager (BiTE) antibodies for hematological cancers from AstraZeneca's MedImmune LLC subsidiary, ending a 2003 deal. MedImmune returned North American...
07:00 , Apr 13, 2009 |  BC Week In Review  |  Clinical News

Micromet, AstraZeneca preclinical data

Data published in the Journal of Immunotherapy showed that bispecific single-chain antibodies (bscAbs) targeting carcinoembryonic antigen (CEA) and CD3 prevented growth of human colorectal cancer in an immunodeficient mouse model. Additionally, a murine surrogate...